Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 5Unknown 2Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Gynecologic 2Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1HER2-low Breast Cancer 1Cervical Cancer Recurrent 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × RC48 antibody × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
37 enrolled
Breast

HER2-low Breast Cancer

NCT07285941 2025-12-16

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

Zhejiang Cancer Hospital

Phase 2 Recruiting
20 enrolled
Gynecologic

Ovarian Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
74 enrolled
Breast

Breast Neoplasms

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Gynecologic

Cervical Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡